Considering Triplet Therapy for Nondriver NSCLC

Video

Considering Triplet Therapy for Nondriver NSCLC

A 64-Year-Old Woman With Metastatic NSCLC

  • A 64-year-old woman reported having cough and shortness of breath on exertion for the past 2 years, but now having persistent symptoms even without exertion.
    • PE: revealed diminished breath sounds and minimal expiratory wheezing in right lung; not physically fit
    • PMH: mild hypertension well managed on lisinopril
    • SH: smoker, 15 pack-years
  • CT scan revealed 2 masses in RUL and several small masses in the liver
  • Biopsy of right lung mass confirmed grade 2 adenocarcinoma
    • EGFRnegative,KRASnegative
    • IHC negative forALK-rearrangement,ROS1-rearrangement
    • PD-L1 TPS: 56%
  • PET scan showed multiple areas of FDG uptake in liver, SUVmax, 7.8
  • Brain MRI, negative for metastases
  • Diagnosis: stage IV lung adenocarcinoma
  • Patient started on treatment with pembrolizumab/pemetrexed/carboplatin
Related Videos
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
Discussing Response of Amivantamab in EGFR Exon 20+ NSCLC

Discussing Response of Amivantamab in EGFR Exon 20+ NSCLC

December 4th 2023
Article

In the second article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses the results of the phase 1 CHRYSALIS study of amivantamab for patients with EGFR exon 20 insertion-mutated NSCLC.

Read More

Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen

Telisotuzumab Vedotin Elicits Compelling Data in EGFR-Mutant, c-Met NSCLC

Telisotuzumab Vedotin Elicits Compelling Data in EGFR-Mutant, c-Met NSCLC

November 29th 2023
Article

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

Read More

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

January 15th 2021
Podcast

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

Listen

FDA to Review sBLA for Amivantamab Plus Chemo in EGFRm Advanced NSCLC

FDA to Review sBLA for Amivantamab Plus Chemo in EGFRm Advanced NSCLC

November 20th 2023
Article

Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.

Read More

Promising ADCs Emerge in Non-Small Cell Lung Cancer

Promising ADCs Emerge in Non-Small Cell Lung Cancer

November 18th 2023
Article

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.

Read More